Puma Biotechnology (NASDAQ:PBYI) Issues Earnings Results

Puma Biotechnology (NASDAQ:PBYI) announced its earnings results on Thursday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.09, FiscalAI reports. The company had revenue of $44.81 million for the quarter, compared to analyst estimates of $42.00 million. Puma Biotechnology had a return on equity of 20.81% and a net margin of 10.69%.

Here are the key takeaways from Puma Biotechnology’s conference call:

• ALISCA‑Lung1 interim: higher‑dose alisertib (60 mg) showed a median PFS of 4.2 months versus 1.7 months at 50 mg and activity is enriched in c‑MYC‑high tumors; dose escalation to 70 mg and a combination ALISCA‑Lung2 (with paclitaxel) are planned for H2 2026.
• ALISCA‑Breast1 interim: alisertib plus endocrine therapy showed median PFS ~5.45–5.59 months in the 40–50 mg arms with stronger efficacy in biomarker subgroups (PIK3CA wild‑type, ESR1‑mutant and high c‑MYC); enrollment will be expanded to biomarker‑focused cohorts and updated data are expected H2 2026.
• Financials & guidance: raised FY2026 net NERLYNX product revenue guidance to $202–206M, expects FY net income of $16–19M, and is now debt‑free after the final Athyrium payment with ~$101.5M in cash/marketable securities as of 3/31/2026.
• Q1 commercial softness: Q1 net product revenue fell to $42.0M (2,328 ex‑factory bottles, down ~29% QoQ) driven in part by an estimated ~439‑bottle inventory drawdown at specialty channels; TRXs were down ~4% QoQ and demand declined ~6% QoQ despite higher NRX and enrollment trends.

Puma Biotechnology Trading Up 3.2%

Shares of PBYI stock traded up $0.23 on Friday, reaching $7.49. 755,011 shares of the stock were exchanged, compared to its average volume of 267,164. The business’s 50 day moving average price is $6.81 and its 200 day moving average price is $6.19. The company has a market capitalization of $381.17 million, a price-to-earnings ratio of 15.60 and a beta of 1.24. Puma Biotechnology has a twelve month low of $2.85 and a twelve month high of $7.90.

Hedge Funds Weigh In On Puma Biotechnology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Dimensional Fund Advisors LP grew its stake in shares of Puma Biotechnology by 5.3% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,339,603 shares of the biopharmaceutical company’s stock worth $7,971,000 after purchasing an additional 67,725 shares in the last quarter. O Shaughnessy Asset Management LLC grew its stake in shares of Puma Biotechnology by 35.3% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock worth $6,666,000 after purchasing an additional 292,108 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Puma Biotechnology by 1.1% during the fourth quarter. Geode Capital Management LLC now owns 994,345 shares of the biopharmaceutical company’s stock worth $5,917,000 after purchasing an additional 10,823 shares in the last quarter. Russell Investments Group Ltd. grew its stake in shares of Puma Biotechnology by 4,823,365.0% during the third quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock worth $5,123,000 after purchasing an additional 964,673 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Puma Biotechnology by 17.2% during the fourth quarter. State Street Corp now owns 877,077 shares of the biopharmaceutical company’s stock worth $5,219,000 after purchasing an additional 128,419 shares in the last quarter. Institutional investors and hedge funds own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

PBYI has been the topic of a number of research analyst reports. Weiss Ratings reissued a “hold (c+)” rating on shares of Puma Biotechnology in a research report on Tuesday, April 21st. Wall Street Zen raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 21st. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, Puma Biotechnology currently has an average rating of “Hold”.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.